Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 1996 Jun;34(6):1016-21.

Cyclosporine in severe childhood atopic dermatitis: a multicenter study.

Author information

  • 1Department of Dermatology, Walsgrave Hospital, Coventry, U.K.

Abstract

BACKGROUND:

Severe atopic dermatitis (AD) remains difficult to treat. Cyclosporine is effective in adults but has not previously been investigated in children with AD.

OBJECTIVE:

The aims were to investigate the efficacy, safety, and tolerability of cyclosporine in severe refractory childhood AD.

METHODS:

Subjects 2 to 16 years of age were treated for 6 weeks with cyclosporine, 5 mg/kg per day, in an open study. Disease activity was monitored every 2 weeks by means of sign scores, visual analogue scales for symptoms, and quality-of-life questionnaires. Adverse events were monitored. Efficacy and tolerability were assessed with five-point scales.

RESULTS:

Twenty-seven children were treated. Significant improvements were seen in all measures of disease activity. Twenty-two showed marked improvement or total clearing. Quality of life improved for both the children and their families. Tolerability was considered good or very good in 25 subjects.

CONCLUSION:

Cyclosporine may offer an effective, safe, and well-tolerated short-term treatment option for children with severe AD.

Comment in

PMID:
8647967
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk